GlobeStar Therapeutics Corporation
GSTC · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.03 | 0.02 |
| FCF Yield | -2.25% | -1.10% | -4.74% | -4.30% |
| EV / EBITDA | 3,461.44 | -8.71 | -8.20 | -7.15 |
| Quality | ||||
| ROIC | 14.89% | 14.84% | 13.48% | 26.97% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.10 | 0.07 | 0.26 | 0.21 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -64.76% | 71.07% | 41.12% | -80.94% |
| Safety | ||||
| Net Debt / EBITDA | 921.59 | -2.00 | -2.41 | -1.27 |
| Interest Coverage | -44.84 | -22.77 | -19.78 | -4.59 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |